Investitionsthese
Pureos Bioventures invests in biotech companies developing innovative therapeutics, with a focus on next-generation biological drugs and drug formats. They aim to impact patients’ lives by advancing treatments for severe diseases, particularly in oncology, fibrosis, rare neurological disorders, and inflammatory diseases.
Investitionsphase
Preclinical to clinical-stage biotech companies
Bevorzugte Reifephase für die erste Finanzierung.
Sektoren & Themen
Innovative therapeutics, next-generation biological drugs, antibody-drug conjugates (ADCs), gene therapies, and precision monoclonal antibodies
Thematische Schwerpunkte und Zielmarktsegmente von Interesse.
Ticketgröße
k.A.
Standard-Finanzierungsbetrag pro Runde.
Outreach & Dossier-Analysen
Verifiziertes E-Mail-Muster
Analysen-Scorecard der Investitionsthese
Unser KI-Analyzer hat Portfolio-Unternehmen gescannt und verifizierte Übereinstimmungen berechnet...
Investment Team (28)
B
Ben Morgan
General Partner Board
D
Dominik Escher
Managing Partner
D
Dr. Anne Grahl
Investment Manager
D
Dr. Bruno Teta
Pureos Partners Board
D
Dr. Butrint Aliu
Analyst
D
Dr. Dominik Escher
Managing Partner
D
Dr. Dragan Grabulovski
Venture Partner
D
Dr. Klaus Breiner
Managing Partner
D
Dr. Lars Nieba
Venture Partner
D
Dr. Martin Münchbach
Managing Partner
D
Dr. Mathieu Simon
Advisory Board
D
Dr. Matthias Staehelin
Pureos Partners Board
D
Dr. Omar Khwaja
Advisory Board
D
Dr. Omar Khwaja, MD PhD
Advisory Board
D
Dr. Roberto Iacone
Venture Partner
D
Dr. Sonia Quaratino
Advisory Board Member
D
Dr. Sonia Quaratino, MD PhD
Advisory Board
D
Dr. Veronica Gambillara Fonck
Partner
D
Dr. Ximing Ding
Principal
I
Ian Metcalfe
Venture Partner
K
Karen Haith
General Partner Board
M
Martin Münchbach
Managing Partner and Founding Partner
P
Pascal Mahieux
General Partner Board
P
Prof. Dr. Bernd Seizinger
Advisory Board
P
Prof. Dr. Roger Nitsch
Advisory Board
P
Prof. Dr. Sai Reddy
Venture Partner
P
Prof. Dr. Thomas Baumert
Advisory Board Member
S
Stefano Lamaro
Analyst